Our data suggest that loss of IGF-1R expression renders endocrine-resistant breast cancer cells more sensitive to insulin, probably due to increased insulin binding sites [45], which activates the overlapping pro-tumorigenic pathways to IGF-1R. This evidence concerns the gene INS and breast cancer.